Selective Estrogen Receptor Modulators
-
Subject Areas on Research
- 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.
- 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
- Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
- Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
- Breast cancer. Clinical practice guidelines in oncology.
- CYP2D6 testing in breast cancer: ready for prime time?
- Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM.
- Chemoprevention of prostate cancer.
- Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis.
- Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
- Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting.
- Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.
- Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.
- Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics.
- Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
- Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
- Elucidation of the molecular mechanism of action of selective estrogen receptor modulators.
- Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.
- Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
- Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
- From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
- Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
- Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
- Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.
- Managing menopause.
- Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators.
- Mining the complexities of the estrogen signaling pathways for novel therapeutics.
- Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
- Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
- Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay.
- Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.
- Relationship between tamoxifen use and high risk endometrial cancer histologic types.
- Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
- Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis.
- Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen.
- Structural basis for an unexpected mode of SERM-mediated ER antagonism.
- Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
- Testing whether decision aids introduce cognitive biases: results of a randomized trial.
- The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.
- The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.
- The molecular determinants of estrogen receptor pharmacology.
- The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
- The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.
- The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
- Use of alternative therapies in menopause.
- Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
- Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
- Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
- McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Duke Innovation & Entrepreneurship